poisar

Stocks · News reference

Corvus Pharmaceuticals Says Phase 1/1b Soquelitinib T Cell Lymphoma Data Published In Blood Showed Objective Responses In 9 Of 24 Patients, Median Overall Survival Of 28.1 Months

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CRVS
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Benzinga Insights

    Corvus Pharma Q2 2026 Earnings Call Transcript

    Corvus Pharma (NASDAQ:CRVS) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by

    CRVS
  3. Benzinga Newsdesk

    Corvus Pharma Q2 EPS $(0.19) Misses $(0.17) Estimate

    Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 11.76 percent. This is a 90 percent decrease over losses of $(0.10) per share from the

    CRVS